Cassava Sciences Slides After Releasing Data On Its Alzheimer's Drug

(RTTNews) - Cassava Sciences, Inc. (SAVA) shares are sliding more than 14 percent on Friday morning trade, despite the company saying biomarker data with Simufilam in Alzheimer's disease is positive. There have been reports of a few researchers questioning the results.

The company said Simufliam showed improvements in all measured biomarkers of disease and improved cognition.

Cassava Sciences will give a live podium presentation today at the Alzheimer's Association International Conference in Denver, CO, and virtually.

The shares gained initially and is currently at $88.57, down 14.30 percent from the previous close of $103.35 on a volume of 5,979,437. For the 52-week period, the shares have traded in a range of $2.78-$146.16 on average volume of 2,962,009.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More